From launching the first product to determine Rh+ or Rh- blood type, developing the world's first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years. The company is powered by Ortho Care ™, an award-winning, holistic service and support program that ensures best-in-class technical, field and remote service and inventory support to laboratories in more than 130 countries and territories around the globe. For more information, visit Ortho's website or social media channels: LinkedIn, Twitter, Facebook and YouTube. i 95% CI: 99.1-100% ii 90% sensitivity and positive agreement on samples from 40 discrete individuals confirmed positive to COVID-19 by PCR tested greater than 15 days after symptom onset. Data on file.